“…The experimental group showed lower rate of anemia (RR 0.72, 95% CI 0.55 to 0.96, P = 0.02) than the control group. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Precipitating factors were anemia (OR = 2.42; 95%CI: 1.16-5.02; p = 0.021), progressive valvular heart disease (OR = 3.52; 95%CI: 1.35-7.85; p = 0.009), acute kidney injury (OR = 6.98; 95%CI: 2.32-20.96; p < 0.001), time to diuretic administration >60 minutes after ED arrival (OR = 3.89; 95%CI: 2.16-7.00; p < 0.001), and no discharge advice for follow-up (OR = 2.30; 95%CI: 1.10-4.77; p = 0.028). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Progression of renal anemia has been shown to be associated with advanced renal tubulointerstitial lesions. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Other hematological toxicities of grade 3 or higher were as follows: neutropenia in 3 (10.0%), leukopenia in 3 (10.0%), and anemia in 2 (6.7%) patients. Most frequent non-hematological toxicity of grade 3 was anorexia (n = 4, 13.3%) and general fatigue (n = 3, 10.0%); no grade 4 non-hematological toxicities were observed. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The most common treatment-related AEs of any grade were asthenia, anemia, decreased appetite, increased blood cholesterol, increased blood triglycerides, decreased white blood cell count, and increased low-density lipoprotein. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Neutropenia (37.3%), anemia (6.0%), and diarrhea (6.0%) in the FFN group and neutropenia (22.2%) and thrombocytopenia (18.5%) in the GemNab groups were the most frequent grade 3–4 side effects. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The most common treatment-related adverse effects were leukopenia, neutropenia, anemia, ALT/AST elevation, and nausea. Biomarker analysis showed that none of PD-L1 expression, TMB level, and CD8 + TIL density could serve as a predictive biomarker. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The most common hematologic AEs were thrombocytopenia and anemia, with highest rates of Grade ≥3 events in high‐risk patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A paciente apresentou anemia hemolítica microangiopática (hemoglobina 5,3 g/dL; VCM 104 fl, esquizócitos em sangue periférico), trombocitopenia grave (5.000/mm(3) plaquetas) e envolvimentos neurológico e cardíaco, característicos de PTT. …”
Enlace del recurso
Enlace del recurso

“…Frequently reported treatment-emergent adverse events (TEAEs) of any grade were hematological: leukopenia (94.1%), neutropenia (88.2%), anemia (64.7%), and thrombocytopenia (47.1%). Grade 3–4 TEAEs included neutropenia (64.7%) and leukopenia (47.1%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The initial laboratory results revealed anemia (hemoglobin 5.2 g/dL), hyperkalemia (6.3 mmol/L), elevated creatinine (4.50 mg/dL, with a baseline of 0.9mg/dL). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…No significant difference was found in anemia, radiation enteritis, radiation proctitis, or radiation cystitis between the groups. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Thus, it can serve as a valuable indicator of iron homeostasis and prognosis even in patients without iron deficiency or anemia. Further studies are needed to confirm the results and to investigate therapeutic implications. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…IMPORTANCE: Intravenous iron is recommended by many clinical guidelines based largely on its effectiveness in reducing anemia. However, the association with important safety outcomes, such as infection, remains uncertain. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Both plants extracts reduced parasitemia level, prevented anemia and improved bodyweight of treated mice. Comparative results from all tested parameters showed that the best activities were observed with C. citratus treated groups of mice.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Household ESF coverage was associated with a lower likelihood of abnormal results for biomarkers related to anemia (marginal effect between − 2.16 and − 2.18 percentage points), kidney failure (between − 1.01 and − 1.19 p.p.), and arterial hypertension (between − 1.48 and − 1.64 p.p). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Among Extraintestinal symptoms (EIs) a decrease of anemia (76%VS43%, p = 0,001) is observed. Failure to Thrive (FTT) is stable throughout the years (p = 0.03), while screenings show a trend of increment (19%VS23%). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Patients with recurrent episodes of internal hemorrhoidal bleeding and chronic anemia treated by SRAE in three tertiary hospitals between March 2017 and June 2020 were retrospectively evaluated. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…EFS and OS were not significantly different between the GCB and ABC subtypes. Grade III/IV anemia, neutropenia, and thrombocytopenia were seen in 7.6%, 13.6%, and 2.7% of patients, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso